Treatment of metastatic pancreatic adenocarcinoma: a review R Thota, JM Pauff, JD Berlin Oncology (Williston Park) 28 (1), 70-4, 2014 | 194 | 2014 |
Barriers and facilitators to telemedicine: can you hear me now? AM Lopez, K Lam, R Thota American Society of Clinical Oncology educational book. American Society of …, 2021 | 141 | 2021 |
Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study E Culakova, R Thota, MS Poniewierski, NM Kuderer, AF Wogu, DC Dale, ... Cancer medicine 3 (2), 434-444, 2014 | 125 | 2014 |
Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population WI Gonsalves, T Tashi, J Krishnamurthy, T Davies, S Ortman, R Thota, ... Journal of palliative medicine 14 (11), 1231-1235, 2011 | 102 | 2011 |
American Society of Clinical Oncology road to recovery report: learning from the COVID-19 experience to improve clinical research and cancer care NA Pennell, M Dillmon, LA Levit, EA Moushey, AS Alva, S Blau, ... Journal of Clinical Oncology 39 (2), 155-169, 2021 | 94 | 2021 |
Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database R Thota, X Fang, S Subbiah Journal of gastrointestinal oncology 5 (1), 18, 2014 | 80 | 2014 |
Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study ER Ahn, PK Mangat, E Garrett-Mayer, S Halabi, EG Dib, DE Haggstrom, ... JCO precision oncology 4, 757-766, 2020 | 68 | 2020 |
Immune-mediated complications after hematopoietic stem cell transplantation Z Li, SM Rubinstein, R Thota, M Savani, E Brissot, BE Shaw, NS Majhail, ... Biology of Blood and Marrow Transplantation 22 (8), 1368-1375, 2016 | 68 | 2016 |
Telehealth is a sustainable population health strategy to lower costs and increase quality of health care in rural Utah R Thota, DM Gill, JL Brant, TJ Yeatman, DS Haslem JCO Oncology Practice 16 (7), e557-e562, 2020 | 49 | 2020 |
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, ... Annals of Oncology 35 (5), 448-457, 2024 | 40 | 2024 |
An update on gastric cancer SA Ahmad, BT Xia, CE Bailey, DE Abbott, BA Helmink, MC Daly, R Thota, ... Current problems in surgery 53 (10), 449-490, 2016 | 40 | 2016 |
Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a Veterans' Affairs Central Cancer Registry (VACCR) database analysis WI Gonsalves, S Kanuri, T Tashi, I Aldoss, A Sama, I Al‐Howaidi, A Ganta, ... Journal of Surgical Oncology 104 (6), 667-671, 2011 | 40 | 2011 |
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted … JG Fisher, D Tait, E Garrett-Mayer, S Halabi, PK Mangat, JC Schink, ... Targeted oncology 15, 733-741, 2020 | 39 | 2020 |
Trametinib in the treatment of melanoma R Thota, DB Johnson, JA Sosman Expert opinion on biological therapy 15 (5), 735-747, 2015 | 35 | 2015 |
Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? R Thota, RS Gonzalez, J Berlin, DB Cardin, C Shi American Journal of Clinical Pathology 148 (3), 208-214, 2017 | 31 | 2017 |
Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels R Thota, AK Ganti, S Subbiah Journal of thrombosis and thrombolysis 34, 132-134, 2012 | 29 | 2012 |
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR … KA Klute, M Rothe, E Garrett-Mayer, PK Mangat, R Nazemzadeh, KJ Yost, ... JCO precision oncology 6, e2200191, 2022 | 24 | 2022 |
Pembrolizumab in patients with tumors with high tumor mutational burden: results from the targeted agent and profiling utilization registry study HL Duvivier, M Rothe, PK Mangat, E Garrett-Mayer, ER Ahn, ... Journal of Clinical Oncology 41 (33), 5140-5150, 2023 | 20 | 2023 |
A phase II study of ganetespib as second-line or third-line therapy for metastatic pancreatic cancer DB Cardin, R Thota, LW Goff, JD Berlin, CM Jones, GD Ayers, ... American journal of clinical oncology 41 (8), 772-776, 2018 | 18 | 2018 |
Preclinical rationale for the phase III trials in metastatic pancreatic cancer: is wishful thinking clouding successful drug development for pancreatic cancer? R Thota, A Maitra, JD Berlin Pancreas 46 (2), 143-150, 2017 | 16 | 2017 |